ArticleProceedings of the National Academy of Sciences of the United States of America2011
Trypanosoma cruzi as an effective cancer antigen delivery vector.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Promising effects of parasite-derived compounds on tumor regression: a systematic review of in vitro and in vivo studies.Environmental science and pollution research international · 2022Pooled it
- Parasitic Infections and Carcinogenesis: Molecular Mechanisms, Immune Modulation, and Emerging Therapeutic Strategies.Oncology research · 2026Review
- Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool.Probiotics and antimicrobial proteins · 2026Review
- Bridging the gap for diverse applications of parasites as advanced cancer therapeutics: current progress and future directions.Infectious agents and cancer · 2025Review
- Article
- The time has come for a vaccine against Chagas disease.Lancet regional health. Americas · 2025Review
- Kharon Is Crucial forPathogens (Basel, Switzerland) · 2025Article
- Parasites revive hope for cancer therapy.European journal of medical research · 2024Review
- Parasite-enhanced immunotherapy: transforming the "cold" tumors to "hot" battlefields.Cell communication and signaling : CCS · 2024Review
- Cytotoxic Effect ofAdvances in pharmacological and pharmaceutical sciences · 2024Article
- Revisiting the development of Trypanosoma rangeli in the vertebrate host.Memorias do Instituto Oswaldo Cruz · 2024Article
- Anti-Tumor Effect of Protoscolex Hydatid Cyst Somatic Antigen on Inhibition Cell Growth of K562.Acta parasitologica · 2023Article
- ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas' disease.NPJ vaccines · 2023Article
- A novel enemy of cancer: recent investigations into protozoan anti-tumor properties.Frontiers in cellular and infection microbiology · 2023Review
- Review
- Article
- Neospora caninum inhibits tumor development by activating the immune response and destroying tumor cells in a B16F10 melanoma model.Parasites & vectors · 2022Article
- Anti-Tumor Effect of Parasitic Protozoans.Bioengineering (Basel, Switzerland) · 2022Review
- Article
- Synergy betweenJournal for immunotherapy of cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the main challenges in cancer research is the development of vaccines that induce effective and long-lived protective immunity against tumors. Significant progress has been made in identifying members of the cancer testis antigen family as potential vaccine candidates. However, an ideal form for antigen delivery that induces robust and sustainable antigen-specific T-cell responses, and in particular of CD8(+) T lymphocytes, remains to be developed. Here we report the use of a recombinant nonpathogenic clone of Trypanosoma cruzi as a vaccine vector to induce vigorous and long-term T cell-mediated immunity. The rationale for using the highly attenuated T. cruzi clone was (i) the ability of the parasite to persist in host tissues and therefore to induce a long-term antigen-specific immune response; (ii) the existence of intrinsic parasite agonists for Toll-like receptors and consequent induction of highly polarized T helper cell type 1 responses; and (iii) the parasite replication in the host cell cytoplasm, leading to direct antigen presentation through the endogenous pathway and consequent induction of antigen-specific CD8(+) T cells. Importantly, we found that parasites expressing a cancer testis antigen (NY-ESO-1) were able to elicit human antigen-specific T-cell responses in vitro and solid protection against melanoma in a mouse model. Furthermore, in a therapeutic protocol, the parasites expressing NY-ESO-1 delayed the rate of tumor development in mice. We conclude that the T. cruzi vector is highly efficient in inducing T cell-mediated immunity and protection against cancer cells. More broadly, this strategy could be used to elicit a long-term T cell-mediated immunity and used for prophylaxis or therapy of chronic infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.